The gold standard for early detection of prostate cancer, PSA, has recently come under fire for its high rate of false positives. Virginia Hughes investigates some of the researchers hunting for better alternatives and asks whether their promises of creating viable—and profitable—biomarker tests will ever be realized.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer
Communications Biology Open Access 25 June 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stamey, T.A. et al. N. Engl. J. Med. 317, 909–916 (1987).
Getzenberg, R.H. et al. Cancer Res. 51, 6514–6520 (1991).
Leman, E.S. et al. Urology 69, 714–720 (2007).
Brown, D. The Washington Post 26 April 2007, A3.
Underwood, A. Newsweek <http://www.newsweek.com/id/35171> (26 April 2007).
Kramer, B.S. et al. Ann. Intern. Med. 119, 914–923 (1993).
Smith, D.S. et al. Cancer 80, 1852–1856 (1997).
Andriole, G.L. et al. N. Engl. J. Med. 360, 1310–1319 (2009).
Schröder, F.H. et al. N. Engl. J. Med. 360, 1320–1328 (2009).
Esserman, L. et al. J. Am. Med. Assoc. 302, 1685–1692 (2009).
Diamandis, E.P. Clin. Biochem. 40, 1437–1439 (2007).
Shariat, S.F. et al. Clin. Cancer Res. 14, 3785–3791 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, V. Markers of dispute. Nat Med 15, 1339–1342 (2009). https://doi.org/10.1038/nm1209-1339
Issue Date:
DOI: https://doi.org/10.1038/nm1209-1339
This article is cited by
-
Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer
Communications Biology (2022)
